Literature DB >> 27931346

Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.

C Piersimoni1, A Mustazzolu2, A Iacobino2, F Giannoni2, G Santoro3, G Gherardi1, A Del Giudice3, R Perna3, L Fattorini2.   

Abstract

The susceptibility of 253 Mycobacterium tuberculosis complex isolates to pyrazinamide (PZA) was assessed using the BACTECTM MGITTM 960 (M960) system. Resistant strains underwent paired repeat testing using 1) a critical concentration of 200 g/ml (PZA-200), and 2) a reduced inoculum of 0.25 ml. They were also examined using the BACTEC 460 (B460) reference method and investigated for pncA mutations. On M960, 37 isolates were resistant. In the PZA-200 assay, 20 of these were resistant and 17 susceptible, while 18 were resistant and 19 susceptible with reduced inoculum. The B460 assay and pncA sequencing confirmed results with reduced inoculum.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27931346     DOI: 10.5588/ijtld.16.0360

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.

Authors:  Alessandro Mustazzolu; Angelo Iacobino; Federico Giannoni; Claudio Piersimoni; Lanfranco Fattorini
Journal:  J Clin Microbiol       Date:  2017-09-13       Impact factor: 5.948

2.  Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.

Authors:  Glenn P Morlock; Frances C Tyrrell; Dorothy Baynham; Vincent E Escuyer; Nicole Green; Youngmi Kim; Patricia A Longley-Olson; Nicole Parrish; Courtney Pennington; Desmond Tan; Brett Austin; James E Posey
Journal:  Tuberc Res Treat       Date:  2017-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.